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Purpose. To evaluate safety, tolerability and efficacy of varying doses of recombinant
human interleukin-6 (rhIL-6) after chemotherapy.
Patients and Methods. In this phase I-II study, 19 breast (stage III-IV) or non-small
cell lung cancer patients received mitoxantrone (10 mg/m2 ) and thiotepa (40 mg/m2 )
every 3 weeks, followed by rhIL-6 subcutaneously (days 5-15), at six dose levels: 0.5,
1.0, 2.5, 5.0, 10.0 and 20.0 m g/kg body weight/day (m g/kg/d). RhIL-6 was increased to
the next level in the individual patient in case of incomplete bone marrow recovery
(leukocytes <33109/l and/or platelets <1003109/l at day 22) and/or platelet nadir
<253109/l in 2 consecutive cycles.
Results. Flu-like symptoms were observed in most of the patients. Nausea and
vomiting were reported in seven of 48 and 19 of 48 cycles respectively. Dose limiting
toxicity at 20.0 mg/kg/d rhIL-6 consisted of WHO grade 3 to 4 flu-like symptoms,
nausea and vomiting.
Platelet recovery was faster in cycle 1 at 10.0 and 20.0 m g/kg/d rhIL-6 than at lower
dose levels (p<0.05), thrombocytopenia grade 4 was observed at most levels. However,
only two patients needed platelet transfusions (1.0 and 2.5 m g/kg/d rhIL-6). RhIL-6
effects on leukocytes were not dose-related, with a trend for neutrophil nadir to
increase with rhIL-6 up to 10 m g/kg/d. RhIL-6 dose escalation did not affect
hematological parameters and chemotherapy cycle duration. Hemoglobin (p<0.001)
and cholesterol (p<0.05) decreased, while acute phase proteins increased.
Conclusion. RhIL-6 following chemotherapy is tolerable up to 10 m g/kg/d; flu-like
symptoms and nausea were dose limiting at 20 m g/kg/d. Platelet nadir did not differ
for the various rhIL-6 doses. However, a faster platelet recovery was observed at 10.0
and 20.0 m g/kg/d rhIL-6.
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Introduction
Interleukin-6 (IL-6), a 26 kDa protein, is produced in the body by T-lymphocytes,
monocytes, fibroblasts, endothelial cells and keratinocytes [1]. The gene encoding for
IL-6 is located on chromosome 7 and after the cloning of complementary DNA
recombinant human IL-6 (rhIL-6) could be produced [2-6]. IL-6 is a pleiotropic
cytokine with stimulatory actions on hematopoiesis as well as on the immune system
[1], while it is also known to be involved in the acute phase response [7]. In addition
rhIL-6 was found to have growth inhibitory, as well as stimulatory actions on tumor
cells in vitro and on tumor xenografts in mice [8-12]. Other studies, however,
observed no inhibitory or stimulatory effects on tumor cell growth in vitro or in vivo
[13,14].
Special interest in the clinical use of rhIL-6 was raised because of its described
stimulatory effects on the hematopoietic system, especially its effect on
thrombocytopoiesis. In vitro and in vivo rhIL-6 showed proliferative effects on
megakaryocytes [15-17]. In animal studies also effects of rhIL-6 on differentiation of
megakaryocytes, i.e., increase in cell size and ploidy, were observed [15,18,19]. RhIL-6
administered to mice, dogs and non-human primates resulted in elevated peripheral
platelet numbers, due to elevated platelet production [17,20-26]. This was associated
with effects on megakaryocyte differentiation [21,22,24,26]. In animals with bone
marrow depression due to prior whole body irradiation or chemotherapeutic drugs
rhIL-6 administration resulted in a faster recovery of platelets [14,25-29].
Recently, two studies have been published concerning clinical effects of rhIL-6
without chemotherapy, but as yet no full papers have been published concerning the
role of rhIL-6 following chemotherapy [30,31]. Our previous study, by van Gameren
et al., showed rhIL-6 dose-related stimulatory effects on thrombocytopoiesis in
untreated cancer patients. With maximum platelet numbers approximately one week
after the last rhIL-6 administration [31].
In the present study, the safety and tolerability of rhIL-6 after chemotherapy was
evaluated in the same group of patients. The effects on hematological and




Patients. In this phase I-II rhIL-6 study, patients with stage III or IV breast cancer or
disseminated non-small cell lung cancer (NSCLC) received rhIL-6 after combination
chemotherapy. Patients, between the ages of 18 and 70 years, who had received no more than
one prior chemotherapy regimen, with a minimum life expectancy of more than 3 months,
and with a Karnofsky score of 60% or more were eligible. At entry, leukocytes ≥3.03109/l and
platelets ≥1003109/l were required. Patients with severe heart, lung, liver (serum bilirubin
≥40 m mol/l) or renal impairment (serum creatinine >150 m mol/l) were excluded, as were
patients with a history of serious allergic reactions, rheumatoid arthritis, generalized
psoriasis, membranous glomerulonephritis or other autoimmune disease. Concomitant
treatment with other hematopoietic growth factors, cytokines, salicylates or corticosteroids
was not allowed. The study was approved by the Medical Ethical Committee of the University
Hospital of Groningen. All patients gave written informed consent.
Study design. Escherichia coli derived rhIL-6 (108 U/l protein) was provided by Sandoz
Pharma Ltd. (Basle, Switzerland) in 2 mL vials of 150 or 750 m g undissolved lyophilisate.
Increasing dose levels of rhIL-6, 0.5, 1.0, 2.5, 5.0, 10.0 and 20.0 m g/kg/d were studied, with at
least three patients per dose level. Before injection, rhIL-6 was reconstituted with 1 mL of
sterile water. RhIL-6 was injected subcutaneously (sc), once daily by the patient on an out-
patient basis. Prior to chemotherapy rhIL-6 had been administered for seven days, starting
day -15. At day 1 chemotherapy was given intravenously (iv) as a bolus, consisting of
mitoxantrone (Lederle, Etten-Leur, The Netherlands) 10 mg/m2 and thiotepa (Lederle, Etten-
Leur, The Netherlands) 40 mg/m2 both dissolved in 100 ml 0.9% NaCl. Post-chemotherapy,
rhIL-6 was administered in the same dose as pre-chemotherapy for 10 days starting day 5.
The results of the pre-chemotherapy period with rhIL-6 were recently published [31].
Chemotherapy was scheduled every three weeks. In case of incomplete hematological
recovery, i.e., leukocytes <33109/l and/or platelets <1003109/l chemotherapy was postponed
for weekly intervals, for a maximum of four weeks, until bone marrow recovery. No
chemotherapy dose reductions were allowed. The number of chemotherapy cycles
administered depended on the tumor response criteria, i.e., with progressive disease further
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treatment was discontinued. In patients with stable disease, partial response, or complete
response a total of six chemotherapy cycles was foreseen.
RhIL-6 dose was increased to the next higher dose level only in case of incomplete recovery
(leukocytes <33109/l and/or platelets <1003109/l at day 22), and/or when platelet nadir
counts <253109/l had occurred at any time during the previous cycle. These criteria had to be
fulfilled for at least two consecutive chemotherapy cycles. The maximum tolerated rhIL-6
dose was defined as the dose level preceding that at which at least two patients experienced
non-hematological WHO grade 3-4 toxicity or debilitating toxicity leading to discontinuation
of rhIL-6. Acetaminophen, with a maximum of 3 g per day, was administered to prevent fever
or flu-like symptoms. Anti-emetics were prescribed, if necessary, for nausea.
Blood pressure, pulse and temperature were measured twice weekly, as were red blood cell
counts, white blood cell counts and differential counts. Once a week liver (AST, ALT, alkaline
phosphatase and gamma GT) and renal function tests (serum creatinine and BUN) were
performed with subsequent determination of serum levels of sodium, potassium, LDH,
calcium, total protein, albumin, glucose and total cholesterol. C-reactive protein (CRP,
normal value <2 mg/l) and serum amyloid A (SAA, normal value <3 mg/l) were measured
using enzyme-linked immunosorbent assays and determined at days 1, 8, 15 and 22 in cycle 1
and 2 [32].
Prophylactic platelet transfusions were given for platelet levels below 203109/l, red blood
cell transfusions were administered for symptomatic anemia.
Statistical Analysis. The two-tailed Student’s t-test, paired Student’s t-test and the
Wilcoxon test were used for statistical analysis. P values <0.05 were considered significant.
Unless otherwise stated the two-tailed Student’s t-test was used.
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Results
Patient characteristics. Nineteen patients, with a median age of 46 years (range 24-
63), were entered. The characteristics of the patients at each dose level of rhIL-6 are
listed in Table 1. Forty-eight cycles were evaluable for non-hematological toxicity,
whereas 45 cycles could be evaluated for hematological effects. Four patients received
one chemotherapy cycle, six patients received two, five patients received three, three
received four and one patient received five cycles. According to the protocol
chemotherapy dose reduction was not allowed, only chemotherapy postponement.
Therefore, the study was discontinued in six patients for chemotherapy related
hematological causes (WHO grade 4 toxicity), eight patients went off study because of
progressive disease, one patient experienced hematological toxicity as well as
progressive disease, one patient suffered from serious vomiting after the first rhIL-6
injection in the second cycle requiring cessation of rhIL-6 treatment, two patients
experienced severe side effects as well as progressive disease and one patient
discontinued treatment for reasons not related to rhIL-6 administration. Three
patients died during the three month follow up period, all three because of
progressive disease.
Non-hematological toxicity. Forty-eight cycles were evaluable for toxicity. The side
effects of rhIL-6 treatment (including rhIL-6 escalated cycles) are listed in Table 2 and
mainly consisted of flu-like symptoms, i.e., headache, fever, chills and myalgia.
Headache was reported by 13 patients in 26 cycles. Fever was experienced by 16
patients in 29 cycles and occurred within several hours after rhIL-6 injection but dis-
appeared in general before the following injection. Myalgia was reported by seven
patients (13 cycles) and did not occur in patients without fever. Chills were reported
by eight patients (14 cycles), receiving 2.5 m g/kg/d rhIL-6 or more. Four patients 
(7 cycles) experienced nausea, followed incidently by vomiting several hours after
rhIL-6 administration. In nine patients nausea and vomiting was observed shortly
after chemotherapy, and one of these patients required additional anti-emetic therapy
in all four cycles. Erythema at the injection site was observed in 13 patients at all
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rhIL-6 dose steps (25 cycles). These reactions disappeared when the injections were
stopped. Three patients experienced worsening of their dyspnea during rhIL-6 admi-
nistration, which did not exceed WHO grade 2 toxicity. The flu-like symptoms were
prophylactically treated with acetaminophen, requiring a maximum of 3 g a day at
the highest rhIL-6 dose steps. The episodes of nausea were successfully treated with
metoclopramide. At the highest rhIL-6 dose step (20 m g/kg/d), one patient disconti-
nued rhIL-6 administration due to WHO grade 3 fever and severe myalgia, one stop-
ped because of WHO grade 3 nausea and vomiting and the last patient at this dose
level suffered from a combination of headache, fever, myalgia and chills, requiring
cessation of rhIL-6 administration. None of these patients were treated for more than
two cycles. Because of these symptoms 20 m g/kg/d rhIL-6 was considered intolerable.
Table 1. Patient characteristics
rhIL-6 dose 
( m g/kg/d)
0.5 1.0 2.5 5.0 10.0 20.0
No. of patients 3 3 4 3 3 3
Male/female 0/3 0/3 1/3 0/3 1/2 2/1
Age (years)
Median 40 51 44 43 48 51
Range 30-46 44-54 29-63 42-48 24-57 40-61
Cancer diagnosis
Breast 3 3 2 3 0 1
NSCLC 0 0 2 0 3 2
Prior therapy
chemo&radiotherapy 3 3 2 2 1 1
chemotherapy 0 0 0 1 0 2
none 0 0 2 0 2 0
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Table 2. Non-hematological toxicity, listed are the number of cycles in which certain events occurred.
rhIL-6 dose 
(m g/kg/d)
WHO grade 0.5 1.0 2.5 5.0 10.0 20.0
No. of cycles 8 10 7 11 7 5
Headache 1 8 5 3 2 1 1
2 – 1 – 4 – –
3 – – – 1 – –
Fever 1 5 3 2 4 – –
2 1 4 1 1 5 2
3 – – – – – 1
Myalgia 1 3 4 – 2 2 –
2 – – – – – 1
3 – – – – – 1
Chills NA – – 4 3 4 3
N + Va 1 2 – 2 – – –
3 1 – 1 – – 1
N + Vb 1 5 – 1 – – –
2 – – 1 3 – –
3 – – 2 4 1 2
Dyspnea 1 3 – – – – –
2 – – 1 – – 1
Erythema at injection site NA 7 6 5 5 1 1
N + V: nausea and vomiting related to rhIL-6 treatment (a) and chemotherapy (b),
NA: not applicable
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Hematological effects.
Hematological effects of
rhIL-6 could be evaluated in
45 completed cycles. In the
third cycle only nine
patients were available for
analysis, mainly due to dis-
continuation of chemothe-
rapy because of bone mar-
row toxicity and progressive
disease. It was therefore
decided, only to use the first
and second cycle for compa-
rison of the six different
rhIL-6 dose steps.
In Figure 1, the mean
number of platelets for 0.5-
5.0 and 10.0-20.0 m g/kg/d
rhIL-6 in the first cycle are shown. There was no significant difference between
platelets day 1 cycle 1 at the 10.0 and 20.0 m g/kg/d dose versus the lower rhIL-6 dose
steps. For the two highest dose steps the platelet nadir occurred significantly earlier
than for the lower dose steps, day 12 vs day 15 (p<0.02). Although the platelet nadir
was the lowest at 20 m g/kg/d rhIL-6 (48±20 3109/l), it did not differ significantly
from the nadir at the other dose steps (Table 3). A faster recovery of platelets (day 15
through day 22) was observed in the first cycle, at the 10 and 20 m g/kg/d rhIL-6 dose
step compared to the lower dose steps (p<0.05 Wilcoxon). This was in keeping with
the time required for platelets to raise from nadir to 1003109/l, which was median 7
days (range: 4-14) for the lowest dose steps and 5 days (range: 3-9) for 10 and 20
m g/kg/d rhIL-6 (NS). In the second cycle, no patients at the 20 m g/kg/d rhIL-6 dose
level were treated. Furthermore, only one patient was left at the 2.5 m g/kg/d dose level
with exceptionally high platelet numbers. If this patient is excluded from the analysis
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Figure 1. Platelets (3109/l) in the first cycle. l = 0.5-5.0 m g/kg/d
rhIL-6, ll = 10.0-20.0 m g/kg/d rhIL-6 (mean±SD).
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rhIL-6 dose compared to the other dose steps, although this was not statistically
significant. With regard to platelet nadir depth no differences were observed between
the remaining rhIL-6 dose levels in the second cycle. As summarized in table 4, WHO
grade 4 thrombocytopenia occurred in five patients (one from each rhIL-6 dose level,
except for 5.0 m g/kg/d rhIL-6) in cycle 3, 4, 1, 2 and 1, respectively. No thrombocyto-
penic bleeding was observed, however, one patient suffered from serious ecchymoses
after a fall from the stairs with platelets of 40 3109/l, for which platelets were
administered. Two patients, one at 1.0 and one at 2.5 m g/kg/d rhIL-6 received a
platelet transfusion for platelets <20 3109/l without bleeding tendency.
No differences were observed between the various rhIL-6 doses administered and
the mean number of leukocytes and neutrophils during cycle 1 and 2, therefore the
curves in figure 2 and 3 represent all doses. At day 1 of cycle 1 leukocytes and
neutrophils were higher than on day 1 of cycle 2, this will be at least partly an effect
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Figure 2. Leukocytes (3109/l) in cycle 1 ( n ) and in cycle 2 (nn ), 
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Figure 3. Neutrophils (3109/l) in cycle 1 (n ) and in cycle 2 (nn ), for
0.5-20.0 m g/kg/d rhIL-6 (mean±SD).
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neutrophil nadir occurred around day 15 (Fig. 2, 3). The mean neutrophil nadir
(mean ± SD) varied between 0.40±0.15 and 1.10±0.30 3109/l (Table 3), with a trend of
dose related increase from 0.5 up to 10.0 m g/kg/d rhIL-6, however, no statistical
significance could be reached. WHO grade 4 toxicity for leukocytes and for
neutrophils was encountered in 14/45 cycles (Table 4). No neutropenic fever or
bacterially proven infections were observed. The number of monocytes showed a
sharp decrease after chemotherapy administration, but, concurrent with rhIL-6
administration an increase was observed for all dose levels (Figure 4). This increase,
which started 5 days after chemotherapy, occurred when the number of leukocytes
and neutrophils still decreased.
Table 3. Nadir (mean±SD 3109/l) per dose step for leukocytes, neutrophils and platelets in cycle 1 and 2.
Cycle rhIL-6 dose 
(m g/kg/d)
0.5 1.0 2.5 5.0 10.0 20.0
Leukocytes 1 1.60±0.14 2.07±0.49 1.65±0.97 1.77±0.37 1.43±0.39 1.97±0.82
2 1.13±0.12 1.87±0.94 1.501 1.30±0.40 1.10±0.75 NA
Neutrophils 1 0.40±0.15 0.65±0.15 0.90±0.50 0.90±0.10 1.10±0.30 0.80±0.10
2 0.401 0.80±0.36 0.401 0.601 0.90±0.40 NA
Platelets 1 89±10 132±48 124±110 103±27 117±30 48±20
2 74±13 125±85 2271 54±29 88±56 NA
1) sample from one patient, NA: not available.
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Table 4. Hematological toxicity (only grade 3 and 4 are mentioned).
WHO grade rhIL-6 dose 
(m g/kg/d)
0.5 1.0 2.5 5.0 10.0 20.0
No. of cycles 8 10 6 11 7 3
Thrombocytopenia 3 1 2 1 5 0 0
4 1 1 1 0 1 1
Leukopenia 3 4 8 3 7 2 1
4 3 1 2 4 4 0
Neutropenia 3 3 6 1 9 5 0
4 5 4 3 1 0 1
Anemia 3 1 4 0 4 1 1
4 0 0 0 0 0 0
During rhIL-6 administration hemoglobin concentration showed a reversible
decrease of 16 and 18% of the initial level, with the nadir at day 8 and 12 both in cycle
1 and 2 respectively (Figure 5). This decrease in hemoglobin level in both cycles,
which could not be explained by the number of blood samples taken from each
patient, was significantly different compared to the levels at day 1 (p<0.001, paired
Student’s t-test). No rhIL-6 dose response relation could be found for the decrease in
hemoglobin concentration. At the end of each cycle, hemoglobin concentration had
returned to near base-line levels (Figure 5). As summarized in Table 4 anemia never
exceeded WHO grade 3. During the whole study a total of 22 red blood cell
transfusions were administered to 12 patients, with an average of 3.36 red blood cell
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units per transfusion. Reticulocytes, corrected for hematocrit [33], decreased
significantly from 0.64±0.44% (mean±SD) at day 1 to 0.14±0.17% at day 5 (p<0.001).
The reticulocyte nadir occurred approximately one week after chemotherapy (0.12±
0.21%), with increasing levels afterwards and returning to base line levels at day 19.
Chemotherapy postponement, because of incomplete bone marrow recovery,
occurred in 22 of the 45 cycles. In 10/22 cycles this was due to incomplete leukocyte
recovery, in 3/22 cycles the number of platelets had not fully recovered and in 9/22
cycles both leukocytes and platelets were the reason to postpone the next cycle. The
average length of the first cycle was 3.4 weeks (n=19) which increased to 4.2 weeks
(n=13) in cycle 2 (p<0.05) and 4.9 weeks (n=9) in cycle 3 (NS, between cycle 2 and 3).
In five patients rhIL-6 dose was escalated to the next dose level. It concerned two
patients who initially received 0.5 m g/kg/d, two at 1.0 and one at 5.0 m g/kg/d rhIL-6.
One patient (escalated from 0.5 to 1.0 m g/kg/d rhIL-6) experienced worsening of flu-
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Figure 4. Monocytes (3109/l) in cycle 1 ( n ) and in cycle 2 (nn ), 
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Figure 5. Hemoglobin (g/l) in cycle 1 (n ) and in cycle 2 (nn ), 
for 0.5-20.0 m g/kg/d rhIL-6 (mean±SD). Patients were excluded 
from the moment they received blood transfusions.
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In none of the escalated patients rhIL-6 was discontinued because of side effects, in
two patients treatment was discontinued because of progressive disease, the other
three because of WHO grade 4 hematological toxicity and/or prolonged bone marrow
failure, in spite of rhIL-6 escalation.
Biochemical effects. In two patients (2.5 and 10.0 m g/kg/d rhIL-6 respectively) a 4.6
(WHO grade 0) and 2.5 fold increase in AST (WHO grade 0) and a 14.6 (WHO grade
3) and 2.8 fold increase in ALT (WHO grade 0) respectively was observed on day 15 in
the first cycle, with normalization thereafter. In two other patients increasing transa-
minase levels, with concomitant increases in alkaline phosphatase, gamma GT and
bilirubin, during their last cycle of treatment was not related to rhIL-6 administration,
but associated with progressive metastatic liver disease. In the other patients no signi-
ficant changes in liver function tests were observed. Sodium levels did not significant-
ly change during treatment. No renal toxicity was observed, as determined by serum
creatinine levels and BUN. Mean serum LDH levels varied between 220±151 and
334±224 U/l (mean±SD on various days) in cycle 1
and 2, with a tendency to decrease during the cycle.
Total protein (mean±SD: 68±5 and 71±6 g/l in cycle
1 and 2 respectively) and albumin (38±3 and 40±4
g/l) concentrations were stable during all cycles.
Mean CRP and SAA concentrations increased sharply
after the start of rhIL-6 administration and reached
maximum values eight days after chemotherapy
(Table 5). These values normalized before the start of
the next cycle. As shown in Table 5, maximum levels
of these acute phase proteins were similar in cycle 1
and 2. Mean cholesterol concentration for all dose
steps decreased nearly 22% in cycle 1 (p<0.05, paired
Student’s t-test) and 16% in cycle 2 during treatment
with rhIL-6 and returned to base-line levels within
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Figure 6. Cholesterol (mmol/l) in cycle 1 ( n ) and in cycle 2 ( nn ), for
0.5-20.0 m g/kg/d rhIL-6 (mean±SD).
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Table 5. Levels of CRP and SAA, at day 1, day 8 (maximum) and day 22, 
in cycle 1 and 2 (mean±SD).
Cycle Day 1 Day 8 Day 22
CRP (in mg/l) 1 22.9±19.8 212±187 33.7±29.7
2 24.5±22.8 292±114 12.6±1.4
SAA (in mg/l) 1 8.8±9.5 199±166 29.3±29.7
2 6.4±5.8 320±42 2.6±1.4
Discussion
In this phase I-II study the results of rhIL-6 administration after chemotherapy are
presented. Its biological activity in consecutive cycles, as assessed by the effects on the
number of platelets and monocytes, the hemoglobin level, acute phase proteins and
cholesterol levels, was clearly established.
Toxicity was dose limiting at 20 m g/kg/d rhIL-6 because of a combination of
headache, fever, myalgia and chills, as well as serious nausea and vomiting. At lower
doses these side effects were tolerable with the use of acetaminophen and/or
metoclopramide. This toxicity is largely in accordance with the toxic rhIL-6 effects
described in patients not receiving chemotherapy [30,31]. Dose limiting, cardiac
dysrythmia and severe hepato-toxicity as observed by Weber et al. at 30 m g/kg rhIL-6
sc daily for seven days, did not occur in our study [30]. Preliminary data from other
studies, reporting the effects of rhIL-6 after chemotherapy, showed no dose limiting
toxicity up to 10 m g/kg/d rhIL-6 [34,35]. The profile of the observed side effects in
these studies was comparable with our results.
As described earlier, rhIL-6 was administered pre-chemotherapy, with subsequent
increases in platelets and leukocytes at the start of the chemotherapy [31]. However
the depth and moment of platelet and leukocyte nadirs was not affected by this, as no
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differences were observed between cycle 1 and 2. There was a faster recovery of
platelets for the two highest rhIL-6 dose steps (10 and 20 m g/kg/d) in the first cycle,
and for the 10 m g/kg/d rhIL-6 dose step in the second cycle. Grade 4
thrombocytopenia was observed at all dose steps except for 5 m g/kg/d rhIL-6.
However, platelet transfusions were only administered at two patients at lower rhIL-6
doses (1.0 and 2.5 m g/kg/d).
RhIL-6 dose escalation did not prevent chemotherapy postponement, as four out
of five patients required a longer chemotherapy interval than before escalation.
However, cumulative bone marrow toxicity, mainly induced by thiotepa, might have
obscured the beneficial effects of rhIL-6 in consecutive cycles and thus of rhIL-6 dose
escalation [36]. Lestingi et al. observed an amelioration of the chemotherapy induced
thrombocytopenia, with higher nadir levels after rhIL-6 when compared with cycles
without rhIL-6 support [34]. In contrast to our results, they found a better response
at 1 than at 10 m g/kg/d rhIL-6. A faster recovery of platelets was observed by Hamm et
al. at a dose level of 5 m g/kg/d rhIL-6, co-administered with G-CSF. This effect seemed
to diminish in a second cycle [35].
No difference was observed in the mean number leukocytes between the different
rhIL-6 doses. A sharp increase in the number of monocytes occurred just after start of
rhIL-6 administration, while leukocytes and neutrophils still decreased. This increase
was also observed during the prechemotherapy administration of rhIL-6 [30,31]. A
significant, but reversible, decrease in hemoglobin levels was observed after the start
of rhIL-6 administration. Nadir hemoglobin levels occurred between day 8 and 15,
with subsequent rises, while rhIL-6 was still administered. Reticulocytes sharply
decreased after chemotherapy, but these numbers stabilized after initiation of rhIL-6
administration. Furthermore no signs of hemolysis was observed. Anemia during
rhIL-6 administration was reported in several animal and human
studies[25,27,30,31,34,37]. Even without chemotherapy a considerable decrease in
hemoglobin concentration occurred, associated with a decrease in serum iron, while
levels of folate, vitamin B12 and erythropoietin were normal [30,31]. Van Gameren et
al. found normal bone marrow iron stores and increased erythropoietin levels [31].
Because of the speed with which it occurred, it seems unlikely that this anemia was
caused by iron deficiency alone. Although a gradual decrease in hemoglobin is to be
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expected due to the chemotherapy treatment, hemoglobin levels decreased especially
during rhIL-6 administration. Recently, we showed that administration of 150 m g/d
rhIL-6 results in a 18 ± 5% increase in plasma volume [38]. Increases in plasma
volume during rhIL-6 administration were also observed by others[39]. Van Gameren
et al. found a rhIL-6 dose-dependent decrease in hemoglobin, and based on the work
of Nieken et al.[38] and Atkins et al.[39] this may have been due to a rhIL-6 dose-
related increase in plasma volume. These changes in plasma volume may have
affected the concentration of platelets at the moment the decrease in hemoglobin was
maximal. The levels of the acute phase proteins, CRP and SAA, showed an immediate
increase after the start of rhIL-6 administration. The range of the acute phase
response was approximately the same in the first and second cycle, which suggests
equivalent rhIL-6 bioactivity in both cycles. Effects on liver function were minimal, in
one patient WHO grade 3 toxicity was observed, which normalized spontaneously. A
reversible reduction of serum cholesterol was observed during rhIL-6 administration;
whether this is also due to shifts in plasma volume as suggested for the observed
anemia or due to actual decreases still remains to be established. However, decreases
in serum cholesterol have also been observed for other cytokines, i.e., granulocyte-
macrophage colony-stimulating factor and rhIL-3 and this may point to interferences
of these cytokines with cholesterol metabolism rather than to apparent decreases
[40,41].
In conclusion, rhIL-6 can be safely administered after chemotherapy up to doses of
10 m g/kg/d. Dose-limiting side effects were observed at 20 m g/kg/d rhIL-6. A faster
platelet recovery was observed at 10 and 20 m g/kg/d. At these doses, it did not affect
platelet nadir. Phase II/III studies are required to assess the clinical impact of rhIL-6
administration on chemotherapy-induced thrombocytopenia. The number of
monocytes increased following rhIL-6 administration. The cause of rhIL-6 induced
anemia remains unclear and warrants further study.
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